Biocure Technology Inc.
CUREX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -96.90% | -38.71% | -13.31% | 110.79% | -19.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -96.90% | -38.71% | -13.31% | 110.79% | -19.54% |
| Operating Income | 96.90% | 38.71% | 13.31% | -110.79% | 19.54% |
| Income Before Tax | 92.18% | -100.74% | 71.05% | -7,410.28% | 1.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.18% | -100.74% | 71.05% | -7,410.28% | 1.97% |
| Earnings from Discontinued Operations | -- | -- | -- | 93.20% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -72.73% | -- |
| Net Income | 92.18% | -100.75% | 92.40% | -593.06% | 61.78% |
| EBIT | 96.90% | 38.71% | 13.31% | -110.79% | 19.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 88.89% | -100.91% | 91.10% | -817.18% | 95.16% |
| Normalized Basic EPS | 83.33% | 79.17% | 50.00% | -240.63% | 82.35% |
| EPS Diluted | 88.89% | -100.91% | 91.10% | -817.18% | 95.16% |
| Normalized Diluted EPS | 83.33% | 79.17% | 50.00% | -240.63% | 82.35% |
| Average Basic Shares Outstanding | -10.04% | -18.33% | -14.75% | -24.46% | 665.69% |
| Average Diluted Shares Outstanding | -10.04% | -18.33% | -14.75% | -24.46% | 665.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |